STIGALL L. JEREMY 4
4 · ClearPoint Neuro, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
ClearPoint Neuro (CLPT) CBO Jeremy Stigall Receives Award of 51,546 RSUs
What Happened
Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, was granted 51,546 restricted stock units (RSUs) on February 17, 2026. The Form 4 reports the acquisition price as $0.00 (award/derivative grant) — these RSUs are a contingent right to receive common stock rather than an immediate open-market purchase.
Key Details
- Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (filed within the standard 2-business-day window).
- Transaction type/code: Grant/Award (reported as "A"); acquisition price: $0.00.
- Units awarded: 51,546 restricted stock units (each unit converts to one share upon vesting).
- Vesting schedule (per footnote): 20% vests Feb 17, 2027; 40% vests Feb 17, 2028; 40% vests Feb 17, 2029.
- Shares owned after transaction: not disclosed on the Form 4.
- Notes: This is a derivative/compensation grant (RSUs), not a cash purchase or sale.
Context
RSUs are compensation awards that convert into actual shares only when they vest; they do not represent immediately tradable shares. Such grants are common for executives and reflect compensation rather than direct market buying or selling. This filing does not indicate an immediate change in market exposure by the insider until vesting and delivery of shares.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-02-17+51,546→ 51,546 total→ Common Stock (51,546 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
- [F2]The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.